Drug Profile
Research programme: DYRK inhibitors - Eurobio Scientific
Latest Information Update: 30 Aug 2019
Price :
$50
*
At a glance
- Originator Diaxonhit
- Developer Eurobio Scientific
- Class Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Down syndrome
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Down syndrome in USA
- 04 Jul 2013 Preclinical trials in Alzheimer's disease in USA (unspecified route)